Starting May 4, GoodRx will sell Novo Nordisk's oral Ozempic at $149, $199 and $299 a month for 1.5mg, 4mg and 9mg doses.
WW International said the pill will be available through its Med+ subscription programme for people with type 2 diabetes, alongside injectable GLP-1 treatments and nutritional and behavioural support.
Novo Nordisk said the launch follows US Food and Drug Administration approval of the pill form in February, expanding access to oral diabetes and weight-management treatment options.
Will the Ozempic pill's higher doses deliver weight loss results that can finally rival powerful injectable competitors?
As wellness brands sell diabetes drugs, where is the line between democratizing healthcare and medicalizing lifestyle choices?
Is a daily pill with a strict fasting rule truly more convenient for patients than a simple weekly injection?